Ddavp (desmopressin acetate)
Antidiuretic Hormone Injection Ampul (ML); Injection Vial (ML); Oral Tablet
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: desmopressin acetate
Drug class: Antidiuretic Hormone
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ddavp
Indications
The following indications are listed for Ddavp:
- Partial Central Diabetes Insipidus
Also known as: Partial Adh Deficiency Induced Diabetes Insipidus, Partial Neurogenic Diabetes Insipidus, Partial Neurohypophyseal Diabetes Insipidus, Partial Pituitary Diabetes Insipidus, Partial Vasopressin-Sensitive Diabetes Insipidus.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Ddavp 4 Mcg/Ml Ampul | Maintenance | Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day. |
| Ddavp 40 Mcg/10 Ml Vial | Maintenance | Inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day. |
| Ddavp 0.1 Mg Tablet | Maintenance | Take 1 tablet (0.1 mg) by oral route 2 times per day. |
| Ddavp 0.2 Mg Tablet | Maintenance | Take 1 tablet (0.2 mg) by oral route 2 times per day. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Desmopressin Acetate 0.2 Mg Tb | Maintenance | Take 1 tablet (0.2 mg) by oral route 2 times per day. |
| Desmopressin Acetate 0.1 Mg Tb | Maintenance | Take 1 tablet (0.1 mg) by oral route 2 times per day. |
| Desmopressin Ac 4 Mcg/Ml Vial | Maintenance | Inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day. |
| Desmopressin 40 Mcg/10 Ml Vial | Maintenance | Inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day. |
| Desmopressin Ac 4 Mcg/Ml Ampul | Maintenance | Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day. |
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Desmopressin/Glucocorticoids
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Glucocorticoids increase the risk of hyponatremia.(1-4)
CLINICAL EFFECTS: Concurrent use of glucocorticoids may increase the risk of hyponatremia with desmopressin.(1-4)
PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, lamotrigine, loop diuretics, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants).
PATIENT MANAGEMENT: The concurrent use of systemic or inhaled glucocorticoids with desmopressin is contraindicated.(1-4) Desmopressin may be initiated 3 days or 5 half-lives after glucocorticoid discontinuation, whichever is longer. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1)
DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4)
Desmopressin/Loop Diuretics
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Loop diuretics increase the risk of hyponatremia.(1-4)
CLINICAL EFFECTS: Concurrent use of loop diuretics may increase the risk of hyponatremia with desmopressin.(1-4)
PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants).
PATIENT MANAGEMENT: The concurrent use of loop diuretics with desmopressin is contraindicated.(1-4) If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1)
DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4)
There are no severe interactions for this drug.
Moderate Interaction: Assess the risk to the patient and take action as needed.
Desmopressin/Agents With Hyponatremia Risk
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Carbamazepine, chlorpromazine, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants increase the risk of hyponatremia.(1-3)
CLINICAL EFFECTS: Concurrent use may increase the risk of hyponatremia with desmopressin.(1-3)
PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (glucocorticoids, loop diuretics).
PATIENT MANAGEMENT: The concurrent use of agents with a risk of hyponatremia with desmopressin may increase the risk of hyponatremia. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1)
DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4)
Contraindications
There is no enhanced messaging for this drug.
- Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min
- Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hyponatremia
- Kidney disease with likely reduction in glomerular filtration rate (GFr)
- Psychogenic polydipsia
- Chronic heart failure
- Coronary artery disease
- Cystic fibrosis
- Hypertension
- Water intoxication
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Abnormal hepatic function tests
- Anaphylaxis
- Hypertension
- Hyponatremia
- Hypotension
- Seizure disorder
- Water intoxication
Less Frequent
- Abdominal pain with cramps
- Headache disorder
- Nausea
Rare or Very Rare
- Diarrhea
- Disturbance in thinking
- Flushing
- Vulvodynia
- Weight gain
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Hemophilia A | ||
| D66 | ICD10CM | Hereditary factor VIII deficiency |
| Z14.02 | ICD10CM | Symptomatic hemophilia A carrier |
| Nocturnal enuresis | ||
| N39.44 | ICD10CM | Nocturnal enuresis |
| Partial central diabetes insipidus | ||
| E23.2 | ICD10CM | Diabetes insipidus |
| Von willebrand's disease | ||
| D68.0 | ICD10CM | Von willebrand disease |
| D68.00 | ICD10CM | Von willebrand disease, unspecified |
| D68.01 | ICD10CM | Von willebrand disease, type 1 |
| D68.02 | ICD10CM | Von willebrand disease, type 2 |
| D68.020 | ICD10CM | Von willebrand disease, type 2A |
| D68.021 | ICD10CM | Von willebrand disease, type 2B |
| D68.022 | ICD10CM | Von willebrand disease, type 2M |
| D68.023 | ICD10CM | Von willebrand disease, type 2N |
| D68.029 | ICD10CM | Von willebrand disease, type 2, unspecified |
| D68.03 | ICD10CM | Von willebrand disease, type 3 |
| D68.04 | ICD10CM | Acquired von willebrand disease |
| D68.09 | ICD10CM | Other von willebrand disease |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.